[RP1400] ExcelRT™ Reverse Transcription Kit II, 100 RXN

Overview

• Detection kits for ZIKV
• CE-IVD marked version available for in vitro diagnostic use
• Available in TaqMan format for analysis

The Zika Virus (ZIKV) is an emerging mosquito-borne virus that was first identified in Uganda in 1947 in Rhesus monkeys through monitoring of sylvatic yellow fever. During large outbreaks in French Polynesia and Brazil, national health authorities reported potential neurological and auto-immune complications of ZIKV disease. Agencies investigating the Zika outbreaks are finding an increasing body of evidence about the link between ZIKV and microcephaly. Infection with ZIKV may be suspected based on symptoms and recent history (e.g. residence or travel to an area where ZIKV is known to be present). Zika virus diagnosis can only be confirmed by laboratory testing for the presence of ZIKV RNA in the blood or other body fluids, such as urine or saliva.

ZIKV TaqMan RT-PCR Kit, 100 reactions

• Ready to use format, including Master Mix for the target and PCR control to monitor for PCR inhibition and validate the quality
• Specific Primer and Probe mix for the pathogen/virus/viroid of interest
• Primer and Probe mix
• Positive and negative control to confirm the integrity of the kit reagents

ZIKV TaqMan RT-PCR Probe/Primer Set and Controls, 100 reactions

• Specific Primer/Probe mix and Positive Control for the pathogen/virus/viroid of interest
• Nuclease-free water
• Can be used together with Norgen’s RT-PCR Master Mix (#28113) or customer supplied master mix

Details

Supporting Data

Figure 1 / 4

Previous

Next

Click for expanded view

Storage Conditions

All kit components can be stored for 1 year after the date of production without showing any reduction in performance.

All kit components should be stored at -20°C upon arrival. Repeated thawing and freezing (> 2 x) of the Master Mix and Positive Control should be avoided, as this may affect the performance of the assay. If the reagents are to be used only intermittently, they should be frozen in aliquots.

GL12 Technical Parameter：

Matched Rotors for GL12

Features

1. Widely used in the field of biochemistry, biological products, pharmaceutical factory and laboratory.

2. Brushless frequency motor for model GL12 which in great torque, free maintenance, no powder pollution, quick in speed up and down.

3. Model GL12 with the digital display which indicates the speed、time and temperature.

4. Micro computer control, there are 10 kinds of program and 10 kinds of acceleration and deceleration for your choice.

5. There are high speed rotors and low speed rotors for your choice.

6. Electric lid lock, compact design, super speed and imbalance protection.

7. The centrifuge body is made of high-quality steel, safe and reliable.

Model:
GL12

Brand:
Yingtai

Code:
8421199090

Description

The EzRNA™ RNA Capping System is a user-friendly product for post-transcriptional RNA modification. Both Vaccinia Capping Enzyme and 2’-O-Methyltransferase are included in the package, which are able to perform in a single reaction. The Vaccinia Capping Enzyme attach 7-methylguanylate cap (m7Gppp, Cap-0) to the 5′ end of RNA to form m7Gppp5’N-RNA (Cap-0 RNA). The 2′-O-methyltransferase utilizes Cap-0 RNA as a substrate, employing S-adenosine methionine (SAM) as a methyl donor to methylate 2′ -OH of the first nucleotide at the 5′ end of Cap-0 RNA, resulting in the formation of Cap-1 RNA.

Features

• 2’-O-Methyltransferase included for Cap-1 RNA
• High capping efficiency
• High stability
• RNase inhibitor is included to enhance the stability of capping reaction

Application

• Generation of 5’Cap-0 (m7Gppp) and Cap-1 (m7GpppNm-) RNA by enzymatic reaction
• mRNA synthesis for in vitro translation
• Gene expression studies
• mRNA vaccine development and therapeutics

Storage

-20°C for 24 months

The EzRNA™ RNA Capping System is a user-friendly product for post-transcriptional RNA modification. Both Vaccinia Capping Enzyme and 2’-O-Methyltransferase are included in the package, which are able to perform in a single reaction. The Vaccinia Capping Enzyme attach 7-methylguanylate cap (m7Gppp, Cap-0) to the 5′ end of RNA to form m7Gppp5’N-RNA (Cap-0 RNA). The 2′-O-methyltransferase utilizes Cap-0 RNA as a substrate, employing S-adenosine methionine (SAM) as a methyl donor to methylate 2′ -OH of the first nucleotide at the 5′ end of Cap-0 RNA, resulting in the formation of Cap-1 RNA.